Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer

Esteban Ferreiro, Belén López de Uralde, Ricardo Abreu, Rita Abreu, Juan A García-Velasco, Elkin Muñoz
Current drug targets · 2020 · vol. 21(9) , pp. 910–921 · doi:10.2174/1389450121666200220124607 · PMID:32077823 · W3008870533
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Aromatase inhibitors, combined with gonadotropins, are a safe and effective option for ovarian stimulation in breast cancer patients undergoing fertility preservation via oocyte vitrification.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Breast cancer is the most common malignancy diagnosed in women, and its treatment has a high probability of loss of fertility. Oocyte vitrification is the most commonly used technique to preserve fertility before starting oncological treatment. Aromatase inhibitors induce hypoestrogenemia while promoting the release of gonadotropins and constitute an alternative drug for ovarian stimulation in patients with breast cancer. OBJECTIVE: In this mini-review, we update and describe the current status of aromatase inhibitor use in controlled ovarian stimulation for oocyte vitrification in patients with breast cancer. RESULTS: Aromatase inhibitors are commonly used in combination with gonadotropins for ovarian stimulation in patients with breast cancer who preserve their fertility through oocyte vitrification. They achieve similar ovarian responses as conventional ovarian stimulation protocols in regards to the number of oocytes, and no additional complications after their use have been reported. Furthermore, aromatase inhibitors seem to be safe not only for offspring, as no more congenital defects occur in newborns from pregnancies achieved after their use, but also for the patients, as no more malignancy recurrence or increased mortality was found in cohort studies. CONCLUSION: Aromatase inhibitors are elective drugs for ovarian stimulation in patients with breast cancer who decide to preserve their fertility through oocyte vitrification.

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Aromatase Inhibitors Breast Neoplasms Breast Neoplasms Ovulation Induction Adult Aromatase Inhibitors Aromatase Inhibitors Breast Neoplasms Breast Neoplasms Endometriosis Endometriosis Female Fertility Preservation Fertility Preservation Fertility Preservation Humans Oocytes Oocytes Oocytes Ovulation Induction

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (89)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-05-11T03:55:33.861732+00:00
pubmed
last seen: 2026-05-13T22:22:11.167363+00:00
License: CC0 · commercial use OK